Knockdown of YAP/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells.

Authors :: Kim YJ
Jang SK
Hong SE
Park CS
Seong MK
Kim HA
Park KS
Kim CH
Park IC
Jin HO
Source :: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Apr 23; Vol. 601, pp. 73-78. Date of Electronic Publication: 2022 Feb 23.
Publication Year :: 2022
Abstract: Although endocrine therapy with tamoxifen has improved survival in breast cancer patients, resistance to this therapy remains one of the major causes of breast cancer mortality. In the present study, we found that the expression level of YAP/TAZ in tamoxifen-resistant MCF7 (MCF7-TR) breast cancer cells was significantly increased compared with that in MCF7 cells. Knockdown of YAP/TAZ with siRNA sensitized MCF7-TR cells to tamoxifen. Furthermore, siRNA targeting PSAT1, a downstream effector of YAP/TAZ, enhanced sensitivity to tamoxifen in MCF7-TR cells. Additionally, mTORC1 activity and survivin expression were significantly decreased during cell death induced by combination treatment with YAP/TAZ or PSAT1 siRNA and tamoxifen. In conclusion, targeting the YAP/TAZ-PSAT1 axis could sensitize tamoxifen-resistant MCF7 breast cancer cells by modulating the mTORC1-survivin axis.<br />Competing Interests: Declaration of competing interest The authors have no conflict of interest to declare.<br /> (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)